实用心脑肺血管病杂志
實用心腦肺血管病雜誌
실용심뇌폐혈관병잡지
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
2015年
7期
89-91
,共3页
刘仁杰%段天林%史广超%邢亚恒
劉仁傑%段天林%史廣超%邢亞恆
류인걸%단천림%사엄초%형아항
小细胞肺癌%顺铂%依托泊苷%治疗结果%疗效比较研究
小細胞肺癌%順鉑%依託泊苷%治療結果%療效比較研究
소세포폐암%순박%의탁박감%치료결과%료효비교연구
Small cell lung cancer%Cisplatin%Etoposide%Comparative effectiveness research
目的：比较不同顺铂给药方案联合依托泊苷治疗广泛期小细胞肺癌（ SCLC）的近期疗效及安全性。方法选择2011年10月—2014年12月在许昌市中心医院呼吸科住院治疗的广泛期SCLC患者95例，随机分为A组34例、 B组34例和C组27例。 A组患者给予顺铂80 mg／m2，第1天； B组患者给予顺铂40 mg／m2，第1～3天； C组患者给予顺铂20 mg／m2，第1～5天。3组患者均联合依托泊苷进行治疗，3周为1个化疗周期。比较3组患者近期疗效、毒副作用及用药依从性。结果因消化道反应不能耐受继续治疗而退出试验者11例，其中A组8例、 B组2例、 C组1例。3组患者近期疗效比较，差异无统计学意义（u＝0.341， P＝0.843）。 A组患者Ⅲ～Ⅳ度恶心、呕吐发生率高于B组和C组（ P＜0.05）。3组患者Ⅱ～Ⅲ度白细胞计数减少和Ⅰ～Ⅲ度脱发发生率比较，差异无统计学意义（ P＞0.05）。 A组患者用药依从率低于B组和C组（ P＜0.05）。结论顺铂3 d、5 d连续给药联合依托泊苷治疗广泛期SCLC的近期疗效肯定，较大剂量一次给药消化道反应轻，患者用药依从性良好。
目的：比較不同順鉑給藥方案聯閤依託泊苷治療廣汎期小細胞肺癌（ SCLC）的近期療效及安全性。方法選擇2011年10月—2014年12月在許昌市中心醫院呼吸科住院治療的廣汎期SCLC患者95例，隨機分為A組34例、 B組34例和C組27例。 A組患者給予順鉑80 mg／m2，第1天； B組患者給予順鉑40 mg／m2，第1～3天； C組患者給予順鉑20 mg／m2，第1～5天。3組患者均聯閤依託泊苷進行治療，3週為1箇化療週期。比較3組患者近期療效、毒副作用及用藥依從性。結果因消化道反應不能耐受繼續治療而退齣試驗者11例，其中A組8例、 B組2例、 C組1例。3組患者近期療效比較，差異無統計學意義（u＝0.341， P＝0.843）。 A組患者Ⅲ～Ⅳ度噁心、嘔吐髮生率高于B組和C組（ P＜0.05）。3組患者Ⅱ～Ⅲ度白細胞計數減少和Ⅰ～Ⅲ度脫髮髮生率比較，差異無統計學意義（ P＞0.05）。 A組患者用藥依從率低于B組和C組（ P＜0.05）。結論順鉑3 d、5 d連續給藥聯閤依託泊苷治療廣汎期SCLC的近期療效肯定，較大劑量一次給藥消化道反應輕，患者用藥依從性良好。
목적：비교불동순박급약방안연합의탁박감치료엄범기소세포폐암（ SCLC）적근기료효급안전성。방법선택2011년10월—2014년12월재허창시중심의원호흡과주원치료적엄범기SCLC환자95례，수궤분위A조34례、 B조34례화C조27례。 A조환자급여순박80 mg／m2，제1천； B조환자급여순박40 mg／m2，제1～3천； C조환자급여순박20 mg／m2，제1～5천。3조환자균연합의탁박감진행치료，3주위1개화료주기。비교3조환자근기료효、독부작용급용약의종성。결과인소화도반응불능내수계속치료이퇴출시험자11례，기중A조8례、 B조2례、 C조1례。3조환자근기료효비교，차이무통계학의의（u＝0.341， P＝0.843）。 A조환자Ⅲ～Ⅳ도악심、구토발생솔고우B조화C조（ P＜0.05）。3조환자Ⅱ～Ⅲ도백세포계수감소화Ⅰ～Ⅲ도탈발발생솔비교，차이무통계학의의（ P＞0.05）。 A조환자용약의종솔저우B조화C조（ P＜0.05）。결론순박3 d、5 d련속급약연합의탁박감치료엄범기SCLC적근기료효긍정，교대제량일차급약소화도반응경，환자용약의종성량호。
Objective To compare the short-term clinical effect of different dosing regimens of cisplatin combined with etoposide on extensive small cell lung cancer.Methods From October 2011 to December 2014, a total of 94 patients with extensive small cell lung cancer were selected in Xuchang Central Hospital, and they were randomly divided into A group ( n=34), B group (n=34) and C group (n=27).Patients of A group received cisplatin at the dosage of 80 mg/m2 on the first day; patients of B group received cisplatin at the dosage of 40 mg/m2 on the first day to the third day; patients of C group received cisplatin at the dosage of 20 mg/m2 on the first day to the fifth day.All of the three groups received etoposide at the same time, and treated for 3 weeks as a course.Short -term clinical effect, toxic and side effect, medication compliance were compared among the three groups.Results A total of 11 patients dropped out of this study because of intolerance to continue treatment caused by gastrointestinal reactions, including 8 cases of A group, 2 cases of B group, 1 case of C group.No statistically significant differences of short-term clinical effect was found among the three groups (u=0.341, P=0.843).The incidence ofⅢ-Ⅳgrade nausea and vomiting of A group was statistically significantly higher than that of B group, C group, respectively (P<0.05).No statistically significant differences of incidence of Ⅱ-Ⅲ grade decreased WBC or Ⅰ-Ⅲ grade alopecia was found among the three groups (P>0.05).The medication adherence rate of A group was statistically significantly lower than that of B group, C group, respectively (P<0.05).Conclusion Successive medication of cisplatin (3 or 5 days) combined with etoposide has certain short-term clinical effect on extensive small cell lung cancer, is with mild gastrointestinal reactions and good medication compliance compared with large-dose one-time medication.
